Pancreatic Cancer Drug Pipeline Analysis Report 2025

According to World Cancer Research Fund International, pancreatic cancer is one of the most common cancer globally. The pancreatic cancer treatment options depend on the location and stage of the disease. Major companies and research institutes are working towards developing innovative treatments for pancreatic cancer treatment including development of combination drugs (stereotactic body radiotherapy (SBRT), among others.

Report Coverage

Pancreatic Cancer Drug Pipeline report by the publisher gives comprehensive insights on the pancreatic cancer therapeutic drugs currently undergoing clinical trials and covers various aspects related to the details for each of these drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies . Moreover, the analysis based on efficacy and safety measures outcomes published for the trials will be covered including their adverse effects in pancreatic cancer pipeline landscape.

The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to pancreatic cancer are covered. Moreover, pancreatic cancer collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.

Pancreatic Cancer Drug Pipeline Outlook

Pancreatic cancer is among the most challenging cancer to treat, due to its typical late-stage diagnosis and aggressive nature. Due to the availability of limited effective treatment, there is a high need for the development of innovative therapies to provide effective treatment outcomes. According to Americ an Cancer Society, average lifetime risk of pancreatic cancer is about 1 in 60 in women and 1 in 56 in men. There are two types of pancreatic cancer - pancreatic adenocarcinoma and pancreatic neuroendocrine tumors (nets). The symptoms include jaundice (yellowing of the skin and eyes), unexplained weight loss, digestive issues such as vomiting, nausea among others. The pancreatic report insights cover the pathophysiology and epidemiology of pancreatic cancer, developing treatment, and the progress and future aspects of ongoing clinical trials for treatment of pancreatic cancer in detail.

The treatment options for pancreatic cancer include chemotherapy, targeted therapy and immunotherapy, radiation therapy and others. The chemotherapy treatment includes adjuvant chemotherapy, neoadjuvant chemotherapy, and palliative chemotherapy. Common chemotherapy drugs include gemcitabine, capecitabine, irinotecan and leucovorin among others. The ongoing research on clinical trials aim to identify efficient therapeutic targets, development of novel pancreatic cancer therapeutic drugs which are showing promising for the treatment of pancreatic cancer.

For instance, George Fisher, MD, PhD, Stanford University, collaborated for clinical trial of immunotherapy drug Keytruda (pembrolizumab) for the treatment of pancreatic tumors which have genetic mutation called a mismatch repair defect. This trial has resulted into the FDA approval for the drug. Another ongoing trial at Stanford University is being conducted for 'in-situ vaccines’ which aims to investigate injecting tiny amounts of immune-stimulating agents into solid tumors directly.

Pancreatic Cancer Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of pancreatic cancer drugs candidates based on various segmentations such as:

By Phase

The pipeline assessment report covers 50+ drug analysis based on phase.

• Late-Stage Products (Phase III and Phase IV)
• Mid-Stage Products (Phase II)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Route of Administration

The pancreatic cancer therapeutic assessment covers 50+ drug analysis based on route of administration.

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Others

Pancreatic Cancer Drug Pipeline Analysis by Phases

The pancreatic cancer pipeline analysis covers phase I, phase II, phase III, phase IV, and early phase drugs for pancreatic cancer. The coverage includes in depth analysis of each drug across these phases. According to analysis, majority of the ongoing clinical trials for pancreatic cancer are currently in Phase II of their development.

University of Texas Southwestern Medical Center is conducting a clinical trial for Pioglitazon e to determine whether addition of the pioglitazone oral medication to standard chemotherapy treatment results in improvement of blood tests.

Pancreatic Cancer - Drug Pipeline Analysis by Route of Administration

The route of administration categories covered under pancreatic cancer pipeline report include oral, intravenous, subcutaneous, parenteral and others. The report provides a comparative analysis of the route of administration for each drug in various phases of clinical trials of pancreatic cancer. According to analysis, the oral route accounted for major share of pancreatic cancer clinical trials.

Pancreatic Cancer Drug Pipeline Competitive Dynamics

the report for pancreatic cancer pipeline landscape covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed pancreatic cancer therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of few players involved in pancreatic cancer clinical trials:

• Pfizer Inc.
• Sanofi SA
• Novartis Pharmaceuticals
• Bristol-Myers Squibb
• Eisai Inc.
• AstraZeneca Plc
• GlaxoSmithKline
• F-Hoffmann-La Roche AG
• Others

Pancreatic Cancer Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for pancreatic cancer. Moreover, the section covers product description, trial ID, study type, drug class, mode of administration, and recruitment status among others.

Drug: Exenatide - AstraZeneca

Exenatide is currently under observational phase sponsored by AstraZeneca. The study is being done to assess the risk of developing pancreatic cancer who have initiated exenatide among type 2 diabetes mellitus (T2DM) patients.

Drug: Sunitinib Malate- Pfizer

Sunitinib malate is currently under phase III clinical trials, sponsored by Pfizer. The purpose of the study is to assess the efficiency of sunitinib in patients suffering from advanced pancreatic islet cell tumors. The study will determine the status and size of their tumors, survival, quality of life and safety of the pancreatic cancer therapeutic drug.

Monoclonal Antibody - Hoffmann-La Roche

Monoclonal Antibody trials is currently under phase I clinical trials, developed by Hoffmann-La Roche. The study is being conducted to assess whether the activation of certain immune system cells will be safe and well tolerated in combination with cytotoxic chemotherapy.

Drug: Leucovorin - Sanofi

The study is being conducted to identify whether the addition of oxaliplatin to 5-Fluorouracil (5-FU) and Leucovorin (LV) will improve the Progression-Free Survival for pancreatic cancer. This pancreatic cancer drug candidate is currently under phase III clinical trial, being developed by Sanofi.

Key Questions Answered in the Pancreatic Cancer - Pipeline Assessment Report

• What is the current landscape of pancreatic cancer pipeline drugs?
• Which companies/institutions are developing pancreatic cancer therapeutic drugs?
• How many phase II drugs are currently present in pancreatic cancer pipeline drugs?
• Which company is leading the pancreatic cancer pipeline development activities?
• What is the current pancreatic cancer commercial assessment?
• What are the opportunities and challenges present in the pancreatic cancer drug pipeline landscape?
• What is the efficacy and safety profile of pancreatic cancer pipeline drugs?
• Which companies/institutions are involved in pancreatic cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in pancreatic cancer?

This product will be delivered within 3-5 business days.